Blueprint Medicines Co. (NASDAQ:BPMC) Expected to Post FY2027 Earnings of $5.34 Per Share

Blueprint Medicines Co. (NASDAQ:BPMC) – Equities researchers at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for Blueprint Medicines in a note issued to investors on Monday, May 6th. Leerink Partnrs analyst A. Berens forecasts that the biotechnology company will post earnings of $5.34 per share for the year. Leerink Partnrs has a “Market Perform” rating on the stock. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($5.38) per share.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. The business had revenue of $71.96 million for the quarter, compared to analysts’ expectations of $67.34 million. During the same period last year, the firm earned ($2.65) earnings per share. The business’s quarterly revenue was up 85.5% on a year-over-year basis.

Several other equities research analysts have also recently weighed in on the company. The Goldman Sachs Group boosted their price objective on Blueprint Medicines from $121.00 to $168.00 and gave the stock a “buy” rating in a research note on Monday. HC Wainwright boosted their price objective on Blueprint Medicines from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. SVB Leerink raised Blueprint Medicines from an “underperform” rating to a “market perform” rating and boosted their price objective for the stock from $50.00 to $97.00 in a research note on Monday. JMP Securities boosted their price objective on Blueprint Medicines from $114.00 to $125.00 and gave the stock a “market outperform” rating in a research note on Friday, May 3rd. Finally, Barclays boosted their price objective on Blueprint Medicines from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, May 3rd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $100.31.

Blueprint Medicines Trading Up 0.2 %

Shares of BPMC stock opened at $108.78 on Tuesday. Blueprint Medicines has a 12-month low of $43.89 and a 12-month high of $110.93. The company has a current ratio of 3.76, a quick ratio of 3.61 and a debt-to-equity ratio of 0.67. The stock’s 50-day moving average price is $92.44 and its 200-day moving average price is $82.00. The stock has a market capitalization of $6.66 billion, a price-to-earnings ratio of -22.62 and a beta of 0.65.

Institutional Investors Weigh In On Blueprint Medicines

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Blueprint Medicines by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock worth $564,045,000 after acquiring an additional 147,827 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Blueprint Medicines by 3.2% during the 3rd quarter. Wellington Management Group LLP now owns 5,080,521 shares of the biotechnology company’s stock worth $255,144,000 after acquiring an additional 156,807 shares in the last quarter. Rock Springs Capital Management LP lifted its stake in Blueprint Medicines by 22.8% in the 3rd quarter. Rock Springs Capital Management LP now owns 2,685,294 shares of the biotechnology company’s stock valued at $134,855,000 after buying an additional 498,622 shares in the last quarter. Polar Capital Holdings Plc lifted its stake in Blueprint Medicines by 108.0% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,040,000 shares of the biotechnology company’s stock valued at $52,229,000 after buying an additional 540,000 shares in the last quarter. Finally, Avidity Partners Management LP lifted its stake in Blueprint Medicines by 81.1% in the 3rd quarter. Avidity Partners Management LP now owns 751,600 shares of the biotechnology company’s stock valued at $37,745,000 after buying an additional 336,600 shares in the last quarter.

Insider Activity at Blueprint Medicines

In related news, CFO Michael Landsittel sold 10,000 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $105.00, for a total value of $1,050,000.00. Following the transaction, the chief financial officer now directly owns 47,286 shares of the company’s stock, valued at approximately $4,965,030. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Blueprint Medicines news, CFO Michael Landsittel sold 10,000 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $105.00, for a total value of $1,050,000.00. Following the sale, the chief financial officer now directly owns 47,286 shares of the company’s stock, valued at $4,965,030. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Ariel Hurley sold 1,834 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $103.88, for a total transaction of $190,515.92. Following the completion of the sale, the insider now directly owns 14,913 shares in the company, valued at $1,549,162.44. The disclosure for this sale can be found here. Insiders have sold a total of 104,123 shares of company stock valued at $9,554,679 in the last ninety days. Company insiders own 3.88% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.